Gamitrinib is a geldanamycin derivative possessing a mitochondria-targeting motif, triphenylphosphonium (TPP, highlighted in Figure 2); to achieve selective accumulation in mitochondria[43,44], it can disrupt mitochondrial HSP90 function, leading to mitochondrial dysfunction, increased mitochondrial permeability transition, and apoptosis in cancer cells[45]. Here, HSP90AB1 is linked to cancer.